COVID-19 Lockdown Impacts Among Patients with Cystic Fibrosis: An Italian Regional Reference Centre Experience

Alessandra Boni1, Manuel Murciano1,2, Francesca De Luca1

  • 1Department of Maternal, Infantile and Urological Sciences, Sapienza University of Rome, 155, 00161 Rome, Italy.

Insights

The COVID-19 lockdown positively impacted cystic fibrosis (CF) patients, particularly males, improving weight and body mass index (BMI). Moderate respiratory function patients saw the greatest nutritional benefits, with some lung function stabilization observed.

Area of Science:

  • Medical Science
  • Pulmonology
  • Chronic Disease Management

Background:

  • The COVID-19 pandemic necessitated social distancing measures, impacting chronic disease management.
  • Cystic Fibrosis (CF) patients experienced reduced outpatient visits and social interactions during the Italian lockdown (March-May 2020).

Purpose of the Study:

  • To evaluate the impact of the COVID-19 lockdown on body mass index (BMI) and lung function in cystic fibrosis (CF) patients.
  • To assess changes in nutritional status and respiratory parameters during the lockdown period.

Main Methods:

  • Retrospective review of clinical data from 111 CF patients (pre-lockdown Oct 2019-Mar 2020, post-lockdown May-Oct 2020).
  • Collected data on weight, BMI, and lung function (FEV1, FEF 25-75%, Tiffenau index, CVF).
  • Telephone interviews assessed physical activity, exacerbations, and adherence to therapy, physiotherapy, and diet.

Main Results:

  • Overall increase in weight observed; male patients showed greater improvements in weight, BMI, FEF 25-75%, and Tiffenau index.
  • Severely compromised patients (FEV1 <40%) experienced significant weight and BMI loss.
  • Moderately compromised patients (FEV1 40-70%) showed significant weight and BMI increase, with a slight CVF reduction.
  • Patients reported reduced physical activity but increased adherence to therapy (43%) and physiotherapy (47.6%).

Conclusions:

  • The lockdown period offered benefits for CF patients, particularly in weight management, especially for males.
  • Nutritional status improved most in patients with moderate respiratory function impairment.
  • Lung function showed stabilization or slight improvement, contrasting with the typical annual decline in CF patients.
Abstract

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
220
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
357
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
292
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
501